Dr Iscoe has academic and practical experience in medical sciences, health and wellness. Dr Iscoe has co-founded Advanced Human Imaging in 2014 and served as its CEO from April 2015 until October 2016. She has experience in Type 1 Diabetes and glucose optimization through continuous glucose monitoring systems (CGMS). Her work in Type 1 Diabetes spanned several years and includes publications in multiple international peer-reviewed journals. Her biomedical research has provided insight on the differences between interstitial glucose and blood glucose levels, which result in a measurement reading when using CGMS.

Mr Melby is co-founder & co-Chief Executive Officer of FitLab, an integrated media & technology holding company focused on fitness & sport lifestyle. He is also co-founder of Mayweather Boxing + Fitness. Previously, Mr Melby was Vice President at New Evolution Ventures, where he invested in and operated health clubs worldwide and served as an executive at UFC Gym. Prior to that, he was co-founder of two technology startups (both of which exited to publicly traded companies), a private equity investor with ClearLight Partners and an investment banker with FBR Capital Markets. Mr Melby has not served as a director of any other listed companies in the 3 years immediately before the end of the 2021 financial year.

Mr Prosser has over a decade of experience in technology expansion and monetization. Mr Prosser has been serving on the Board of Directors of numerous ASX listed companies. He is a founder of Canberra Data Centres, which was acquired by Infratil and Commonwealth Superannuation Corporation in 2016.

Mr Low has 23 years of combined experience in accounting, auditing and consultancy, with experience in corporate finance, auditing, and accounting in various industries such as construction, plantation, hotels, property, manufacturing and marketing. Mr Low has served as the director of the Advanced Human Imaging since July 2020. Mr Low started his accounting services practice KL Management Services, based in Petaling Jaya, in 2006. Mr Low has also served the President of IPO Partners Limited, a corporate advisory firm since April 2015, and a director of Round Table Partners Berhad since 2019. Since June 2019, Mr Low has served the Executive Chairman and Chief Executive Officer of Medi Lifestyle Limited, a Healthcare and Wellness company listed in the Singapore Exchange. Prior to his position at KL Management Service, Mr Low worked as an auditor for an international audit firm, an accountant for a Japanese MNC, plus a couple of years as Financial Controller for two public listed companies in Malaysia. Mr Low is currently a director of Singaporean listed company, Medi Lifestyle Limited (appointed 1 June 2019).

Mr Greissing Jr is a Senior Fellow with the Milken Institute, and the CEO of Greissing Strategic Advisors. Previously he was the Executive Director for the Centre of Public Health at the Milken Institute. Before his time with the Milken Institute, he served as a member of the Executive Committee, Global Leadership Team, and Senior Vice President of Corporate Affairs at Sanofi. During his nearly four decades in the biopharmaceutical industry, he led a range of Public Affairs and Global Corporate Affairs teams, first at the Upjohn Company and Pharmacia and later with Sanofi. His strategic approach to stakeholder management included new product launches and a freshness program for life cycle management. Previously he served as President and Chief Executive Officer of Red Line Associates, a consulting firm with clients from the biopharmaceutical, device, food service, and financial industries. Before entering the industry in 1978, he was on the U.S. Senate Intelligence Committee staff, served in the United States Army, and was a military policeman assigned to the Honor Detail at Fort Myer at Arlington Cemetery. He also chairs Corporate Governance Committee and is a member of Risk Management Committee as well as Compensation Committee.

Ms Ingargiola has almost 20 years of experience in public company finance, compliance, capital markets oversight and mergers and acquisitions. She currently serves as Chief Financial Officer of a NASDAQ biotech firm and Audit Chair of several Public companies including AgEagle (NYSE: UAVS), Vision Marine (NASDAQ:VMAR) and Progress Acquisition Corporation (NASDAQ:PGRWU), a new SPAC that recently completed their IPO. She has served multiple public companies in various Officer and Director roles. Ms Ingargiola has helped guide the uplist or IPO of several companies to NASDAQ or the NYSE.

-

-